Dr. Reddy’s launches drug-free migraine management wearable device Nerivio in Germany

10 Apr 2024 Evaluate

Dr. Reddy’s Laboratories has launched the drug-free non-invasive migraine management wearable device Nerivio in Germany through its step-down subsidiary betapharm. The launch marks the company’s entry into digital therapeutics in Europe. Nerivio is approved by the United States Food and Drug Administration (USFDA), and is CE-mark certified in Europe. 

Nerivio was presented in 2023 by Dr. Reddy’s at the DGN Kongress organised by the German Association of Neurology in Berlin, and the 17th European Headache Congress held in Barcelona, Spain. Dr. Reddy’s will present and launch Nerivio during the Neurological Association of South Africa annual congress on April 17, 2024, in the presence of Dr. Stewart Tepper, Professor of Neurology at the Geisel School of Medicine – Dartmouth, and Vice President, New England Institute for Neurology and Headache. In May 2024, Nerivio will also be presented at International Headache Society 2024 iHEAD meeting in Berlin, Germany. In subsequent months, Dr. Reddy’s will launch Nerivio in Spain and the UK.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.


Dr. Reddys Lab Share Price

6279.95 26.70 (0.43%)
29-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1521.95
Dr. Reddys Lab 6279.95
Cipla 1407.55
Zydus Lifesciences 963.50
Lupin 1640.30
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.